Trade Lisata Therapeutics, Inc - LSTA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.89 |
| Open | 2.49 |
| 1-Year Change | -13.84% |
| Day's Range | 2.49 - 2.99 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 3.89 | 0.37 | 10.51% | 3.52 | 4.05 | 3.52 |
| Jan 17, 2025 | 3.70 | 0.39 | 11.78% | 3.31 | 3.78 | 3.31 |
| Jan 16, 2025 | 3.71 | 0.12 | 3.34% | 3.59 | 3.76 | 3.59 |
| Jan 15, 2025 | 3.67 | 0.16 | 4.56% | 3.51 | 3.77 | 3.50 |
| Jan 14, 2025 | 3.60 | 0.26 | 7.78% | 3.34 | 3.64 | 3.31 |
| Jan 13, 2025 | 3.58 | 0.08 | 2.29% | 3.50 | 3.67 | 3.49 |
| Jan 10, 2025 | 3.64 | -0.11 | -2.93% | 3.75 | 3.87 | 3.59 |
| Jan 8, 2025 | 3.69 | -0.11 | -2.89% | 3.80 | 3.80 | 3.64 |
| Jan 7, 2025 | 3.67 | -0.03 | -0.81% | 3.70 | 3.86 | 3.53 |
| Jan 6, 2025 | 3.68 | -0.45 | -10.90% | 4.13 | 4.14 | 3.59 |
| Jan 3, 2025 | 3.74 | 0.17 | 4.76% | 3.57 | 3.94 | 3.44 |
| Jan 2, 2025 | 3.50 | 0.50 | 16.67% | 3.00 | 3.63 | 2.98 |
| Dec 31, 2024 | 2.95 | 0.14 | 4.98% | 2.81 | 2.95 | 2.79 |
| Dec 30, 2024 | 2.91 | -0.05 | -1.69% | 2.96 | 2.96 | 2.79 |
| Dec 27, 2024 | 3.01 | 0.17 | 5.99% | 2.84 | 3.04 | 2.84 |
| Dec 26, 2024 | 3.12 | 0.23 | 7.96% | 2.89 | 3.13 | 2.89 |
| Dec 24, 2024 | 2.96 | 0.00 | 0.00% | 2.96 | 3.09 | 2.88 |
| Dec 23, 2024 | 3.01 | 0.31 | 11.48% | 2.70 | 3.01 | 2.70 |
| Dec 20, 2024 | 2.60 | 0.03 | 1.17% | 2.57 | 2.69 | 2.51 |
| Dec 19, 2024 | 2.51 | -0.06 | -2.33% | 2.57 | 2.59 | 2.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Lisata Therapeutics, Inc Company profile
About Caladrius Biosciences Inc
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).
Financial summary
BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).
Equity composition
Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.
| Industry: | Biotechnology & Medical Research (NEC) |
110 Allen Road
Second Floor
07920
News
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com